Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin

BACKGROUND: The World Health Organization (WHO) End TB Strategy stresses universal access to drug susceptibility testing (DST). DST determines whether Mycobacterium tuberculosis bacteria are susceptible or resistant to drugs. Xpert MTB/XDR is a rapid nucleic acid amplification test for detection of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillay, Samantha, Steingart, Karen R, Davies, Geraint R, Chaplin, Marty, De Vos, Margaretha, Schumacher, Samuel G, Warren, Rob, Theron, Grant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115865/
https://www.ncbi.nlm.nih.gov/pubmed/35583175
http://dx.doi.org/10.1002/14651858.CD014841.pub2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115865/
https://www.ncbi.nlm.nih.gov/pubmed/35583175
http://dx.doi.org/10.1002/14651858.CD014841.pub2

Ejemplares similares